Immunosuppression in kidney donors with rapamycin and tacrolimus. Proinflammatory cytokine expression;Inmunosupresión en Donantes Renales Expresión de Citoquinas Proinflamatorias

Medicina (Argentina)

Volumn 72, Issue 1, 2012, Pages 3-9

  Cicora, Federico ^a,b,c   Roberti, Javier ^d   Lausada, Natalia ^a   González, Pedro ^f   Guerrieri, Diego ^c,e   Stringa, Pablo ^a   Raimondi, Clemente ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b HOSPITAL ALEMÁN   (Argentina)

^c Foundation for the Research   (Argentina)

^d UNIVERSIDAD DE BELGRANO   (Argentina)

^e UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^f Universidad Provincial del Sudoeste   (Argentina)

Author keywords

Preconditioning; Rapamycin; Tacrolimus; Th17; Treg

Indexed keywords

CREATININE; INTERLEUKIN 21; INTERLEUKIN 6; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY TUBULE NECROSIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; COLD ISCHEMIA; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY TRANSPLANTATION; NEPHRECTOMY; NONHUMAN; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; TH17 CELL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; RATS; RATS, WISTAR; REPERFUSION INJURY; SIROLIMUS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862197998     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Diethelm AG, Blackstone EH, Naftel DC, et al. Important risk factors of allograft survival in cadaveric renal transplantation. A study of 426 patients. Ann Surg 1988, 207: 538-48.
2. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996; 155: 1831-40.
3. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6: 652-8.
4. Halloran P, Aprile M. Factors influencing early renal function in cadaver kidney transplants. A case-control study. Transplantation 1988, 45: 122-7.
5. Cicora F, Lausada N, Vasquez DN, et al. Protective effect of immunosuppressive treatment before orthotopic kidney autotransplantation. Transpl Immunol 2011; 24: 107-12.
6. de Vries DK, Lindeman JH, Ringers J, Reinders ME, Rabelink TJ, Schaapherder AF. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am J Transplant 2011; 11: 1064-70.
7. Yang CW, Ahn HJ, Han HJ, et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. Transplantation 2001; 72: 1753-9.
8. Lin A, Sekhon C, Sekhon B, et al. Attenuation of ischemia-reperfusion injury in a canine model of autologous renal transplantation. Transplantation 2004; 78: 654-9.
9. Richer JP, Gibelin H, Planet M, et al. Ischemia-reperfusion injury is associated with inflammatory cell infiltration: evaluation in a pig kidney autotransplant model. Transplant Proc 2000; 32: 482-3.
10. Tahara M, Nakayama M, Jin MB, et al. A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation. Transplantation 2005; 80: 213-21.
11. Zhang Y, Ma Q. The enhancement of cellular cAMP with olprinone protects autotransplanted rat kidney against cold ischemia-reperfusion injury. Transplant Proc 2006; 38: 1580-3.
12. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28:454-67.
13. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9: 641-9.
14. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172: 5149-53.
15. Yang L, Anderson DE, Baecher-Allan C, et al.: IL-21 and TGF-beta are required for differentiation of human T(H)17 cells, Nature 2008, 454: 350-352.
16. Volpe E, Servant N, Zollinger R, et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008; 9: 650-7.
17. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-5.
18. Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990; 79: 161-5.
19. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
20. Niu X, He D, Zhang X, et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol 2010, 71: 334-41.
21. Fantini MC, Rizzo A, Fina D, et al. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol 2007; 37: 3155-63.
22. Ozaki K, Spolski R, Feng CG, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002, 298: 1630-4.
23. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26: 57-79.
24. Baan CC, Balk AH, Dijke IE, et al. Interleukin-21: an interleukin-2 dependent player in rejection processes. Transplantation 2007; 83: 1485-92.
25. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 2003; 102: 4090-8.
26. Cicora F, Lausada N, Vasquez DN, et al. Sirolimus in kidney transplant donors and clinical and histologic improvement in recipients: rat model. Transplant Proc 2010; 42: 365-70.